Literature DB >> 5428782

Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis.

S Eykyn, I Phillips, J Evans.   

Abstract

Six anuric patients with Scribner shunt site infections were treated by intermittent infusion of vancomycin into the shunt, and a satisfactory clinical response was obtained in five. Serum levels of the antibiotic were estimated frequently. From estimating serum levels and the minimum inhibitory concentrations of vancomycin for a range of hospital staphylococci a dose of 1g. vancomycin every seven days is recommended as a suitable schedule for treating staphylococcal infection in this situation.

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5428782      PMCID： PMC1701050          DOI： 10.1136/bmj.3.5714.80

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  4 in total

1.  Vancomycin: report on treatment of patients with severe staphylococcal infections.

Authors:  A A DUTTON; P C ELMES
Journal:  Br Med J       Date:  1959-05-02

2.  Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report.

Authors:  J E GERACI; F R HEILMAN; D R NICHOLS; W E WELLMAN
Journal:  Proc Staff Meet Mayo Clin       Date:  1958-04-02

3.  Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis.

Authors:  D D Lindholm; J S Murray
Journal:  N Engl J Med       Date:  1966-05-12       Impact factor: 91.245
  4 in total
  13 in total

1.  The flora of renal haemodialysis shunt sites.

Authors:  M H Rebel; R Van Furth; P Stevens; L Bosscher-Zonderman; W C Noble
Journal:  J Clin Pathol       Date:  1975-01       Impact factor: 3.411

Review 2.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

3.  Evaluation of an automated fluorescence polarization immunoassay for vancomycin.

Authors:  B H Filburn; V H Shull; Y M Tempera; J D Dick
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

4.  Comparison of fluorescence polarization immunoassay and bioassay of vancomycin.

Authors:  D J Pohlod; L D Saravolatz; M M Somerville
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

5.  Vancomycin: a reappraisal.

Authors:  R Brown; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-22

6.  Pharmacokinetics of vancomycin in patients with various degrees of renal function.

Authors:  G R Matzke; R W McGory; C E Halstenson; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R D Blevins; C E Halstenson; N G Salem; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis.

Authors:  B E Magera; J C Arroyo; S J Rosansky; B Postic
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

9.  Comparison of the effects of three haemodialysis membranes on vancomycin disposition.

Authors:  J Alwakeel; T A Najjar; M J al-Yamani; S Huraib; A al-Haider; H Abu-aisha
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 10.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.